技术特点：

【仿制药开发】基于生物药剂学理论，通过"临床PK参数-处方工艺优化"闭环研发路径，构建体外-体内相关性研究评价体系，确保制剂生物等效性与临床疗效一致性。

【改良型新药】基于改良的临床优势与特点，关联应达到的临床PK特点，整合临床药理与生物药剂学技术平台，运用PK-PD建模与仿真技术建立定量研发策略，实现处方工艺优化与临床开发方案的科学决策，充分凸显改良新药的的临床价值。
【创新药开发】聚焦药物作用机制、体内过程与临床药理研究数据，指导科学合理的临床试验设计，建立临床价值导向的开发策略体系，挖掘创新药的临床精准患者人群与优效的临床适应症，提高创新药上市的成功率。

Technical Features

【Generic Drug Development】: Leveraging biopharmaceutics principles, we implement a closed-loop R&D pathway integrating "Clinical PK Parameters - Formulation Process Optimization" to establish in vitro-in vivo correlation (IVIVC) studies. This ensures therapeutic equivalence between bioequivalence and clinical efficacy outcomes.
【Improved New Drugs】: Building on enhanced clinical advantages and target-specific PK profiles, we synergize clinical pharmacology and biopharmaceutics platforms. Through PK-PD modeling & simulation-driven quantitative strategies, we enable science-based optimization of formulations and clinical development plans, maximizing the therapeutic value of reformulated drugs.
【Innovative Drug Development】: Guided by mechanistic insights into drug action, in vivo processes, and clinical pharmacology data, we design value-oriented clinical trial frameworks. Our precision development strategies identify optimized clinical indications and target patient populations, unlocking superior therapeutic potential for novel drugs.

质量与管理 ：

Quality Management

成熟的人员培训体系 （A mature personnel training system）
“PDCA”质量持续改进体系 （a PDCA-based quality continuous improvement system）
"方案设计-质量管理-风险控制"为核心的三位一体协同管理体系 （A trinity collaborative management system with the core of "scheme design - quality management - risk control"）